This is the text extract for Proposal to amend the listing of benztropine mesylate injections; Closing Date: Closed; Contact: Natalie Davis, browse documents here.

5 December 2011

Proposal to amend the listing of benztropine mesylate injections

PHARMAC has signed a provisional agreement with Invida Australia Pty Ltd and is seeking feedback on the following proposals relating to benztropine mesylate (Cogentin) injections:  benztropine mesylate injection would be amended in Section B and listed in Part II of Section H of the Pharmaceutical Schedule from 1 February 2012 as follows (expressed ex-manufacturer, excluding GST):

Pack size 5 Current price and subsidy in Section B 36.35 Proposed Price and subsidy 95.00

Chemical Benztropine mesylate

Presentation 1 mg per ml, 2 ml ampoule

Brand Cogentin



Cogentin would be funded in Section B of the Pharmaceutical Schedule subject to the current restrictions, which are: a) up to 5 inj available on a PSO; b) only on a PSO. Cogentin would have protection from delisting and subsidy reduction until 1 February 2017.



Feedback sought PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by Friday, 16 December 2011 to: Natalie Davis Therapeutic Group Manager PHARMAC PO Box 10 254 Wellington 6143 Email: natalie.davis@pharmac.govt.nz Fax: 04 460 4995

All feedback received before the closing date will be considered by PHARMAC’s Board (or Chief Executive acting under delegated authority) prior to making a decision on this proposal.

A469883 Page 1 of 2

Background Benztropine is an anticholinergic used for all forms of Parkinsonism. The parenteral formulation (Cogentin) is for use in the emergency treatment of acute drug-induced dystonic reactions. Cogentin has been listed in the Pharmaceutical Schedule since 1994 and is currently restricted to supply of up to 5 ampoules only on a PSO; however, it has never been subject to a supply agreement. Invida Australia Pty Ltd notified PHARMAC of its intention to significantly increase the price of Cogentin. Acceptance of the current proposal would result in a supply agreement taking effect from 1 February 2012 and would provide greater surety around price and ongoing supply. PHARMAC is unaware of any alternative suppliers of benztropine mesylate injections.

A469883

Page 2 of 2